Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus (NASDAQ: SLP) has announced the launch of version 9.8.3 of its GastroPlus software, enhancing its physiologically based biopharmaceutics modeling capabilities. Key updates include improved reporting templates for Monolix, new validated disease populations for NAFL and NASH, a swine PBPK model for veterinary research, and flexible dosing regimen handling. The company aims to strengthen software interoperability and provide researchers with advanced simulation tools. This release reflects the company's ongoing commitment to integrating machine learning and quantitative systems pharmacology in drug development.
Simulations Plus (NASDAQ: SLP) is set to announce its fourth quarter and full year financial results for fiscal year 2022, ending August 31, 2022, following market closure on October 26, 2022. The company will host a conference call at 5:00 PM ET that day, inviting all interested parties to participate. The call can be accessed via registration or by calling in. Simulations Plus has been a key player in the biosimulation market for over 25 years, providing essential software and consulting services for drug discovery and regulatory submissions.
Simulations Plus, Inc. (Nasdaq: SLP) has announced that CEO Shawn O’Connor will present at the Sidoti Fall Small Cap Investor Conference on September 22, 2022, at 10:45 a.m. ET. The conference will be held virtually on September 21-22, 2022, where O’Connor will engage with investors throughout the day. The presentation will be webcast live and available for replay on the Simulations Plus investor page. For additional details about the conference, visit the conference website or contact Brian Siegel at Hayden IR.
Simulations Plus, a leader in biosimulation software, will present at Baird’s 2022 Global Healthcare Conference on September 14, 2022, at 2:00 p.m. ET. CEO Shawn O’Connor will discuss the company's advancements in modeling and simulation for pharmaceutical safety and efficacy. The session will be webcast live and available for replay on the Simulations Plus website. Established for over 25 years, Simulations Plus provides innovative solutions to major pharmaceutical and regulatory agencies worldwide.
Simulations Plus has launched ILDsym™ version 1A, a quantitative systems pharmacology modeling software aimed at enhancing therapy development for Interstitial Lung Disease (ILD)/b) in systemic sclerosis patients. Sponsored by a leading biotech firm, ILDsym is designed to help inform clinical trial designs, potentially addressing the challenges presented by SSc-ILD. The software can model critical disease mechanisms and improve patient outcomes. The company is also positioned to expand ILDsym's application across various diseases due to its customizable nature.
Simulations Plus (NASDAQ: SLP) announces a collaboration with a large pharmaceutical company to enhance its ADMET Predictor® platform. The partner will provide tens of thousands of proprietary pKa measurements to improve prediction accuracy and extend chemical coverage. This initiative aims to reinforce ADMET Predictor as the leading property prediction tool in drug discovery, leveraging advanced machine learning techniques. The collaboration is expected to significantly advance predictive modeling within the pharmaceutical sector.
Simulations Plus (NASDAQ: SLP) announced the presentation of five scientific posters at the PAGE conference in Ljubljana, Slovenia, from June 28 to July 1, 2022. The conference gathered over 600 scientists focused on data analysis through a population approach. Dr. Jonathan Chauvin emphasized the importance of the event for discussing advancements in modeling and simulation, particularly the MonolixSuite platform. New developments presented include algorithms aimed at enhancing NLME modeling, contributing to the increasing adoption of MonolixSuite.
Summary not available.
Simulations Plus (NASDAQ: SLP) has launched a Concierge Program aimed at fostering strategic partnerships with pharmaceutical companies and contract research organizations. This initiative is designed to enhance customer support through regular communication and collaboration, helping clients to expedite their development programs. Notable successes have been reported, including tailored training for regulatory scientists and customized software solutions across North America, Europe, and South America. The program demonstrates SLP's commitment to understanding clients' evolving needs in the pharmaceutical landscape.
Simulations Plus, Inc. (Nasdaq: SLP) reported a 17% total revenue growth for Q3 fiscal 2022, reaching $15.0 million. The software revenue rose by 16% to $9.7 million, while services revenue grew by 19% to $5.3 million. Diluted EPS increased by 11% to $0.20, with a net income of $4.1 million. The company reiterated its full-year revenue guidance of $52-53 million and announced a quarterly dividend of $0.06 per share, payable August 1, 2022.